Comparative efficacy and safety of first‐line treatments for advanced non‐small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta‐analysis

BACKGROUND: Non‐small cell lung cancer (NSCLC) is the predominant type of lung cancer, and most clinically curable patients are diagnosed with locally advanced disease. Although the efficacy of standard platinum‐based chemotherapy doublets is relatively limited. The effect of immune checkpoint inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Rui, Hou, Xiaoming, Yang, Liping, Zhao, Da
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449246/
https://www.ncbi.nlm.nih.gov/pubmed/30734504
http://dx.doi.org/10.1111/1759-7714.12971

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449246/
https://www.ncbi.nlm.nih.gov/pubmed/30734504
http://dx.doi.org/10.1111/1759-7714.12971

Ejemplares similares